Insiders Trades
Cocrystal Pharma, Inc. Stock: price and insider trades · United States
1 insider bought €70k of shares over the last 90 days, the latest filed 06 Aug 2026.
Cocrystal Pharma, Inc.: what insiders have been doing
Cocrystal Pharma, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Cocrystal Pharma, Inc. logged 13 filings by 4 insiders.
Every open-market trade in the period is a purchase: 9 purchases worth €222k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €61k, bought by Frost Phillip Md Et al and made public on 5 August 2026 (0.31% of market cap). The buyers include 1 senior executive.
The latest purchase dates back some time: it was published 72 days ago, on 6 August 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 13 filings, this issuer sits below that mark. Our records for Cocrystal Pharma, Inc. go back to 2021, with 11 purchases and 1 sale on the open market in total.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
24
Thresholds
n/a
Buy Volume
€2M
11 ops. · all time
Sell Volume
€1M
1 ops. · all time
Who traded when
BuySalePhillip Md Et al Frost9 buys
Since the insiders bought
- -3.8%Entry US$1.06 · Close 16 Oct 2026 US$1.02
- -63.2%Entry US$14.04 · Close at T+365 US$5.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cocrystal Pharma, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$8.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.03
Analyst consensus
3 analystsStrong buy
US$6.00Target US$8.00(+677%)US$10.00
Income statement
EBITDA-US$8.6M
Net income-US$8.8M0.0% margin
Valuation
PER (forward)-2.2x
P/Book13.6x
Beta1.48
Balance sheet & cash
Market capUS$19.8M
Total debtUS$1.5M
Free Cash Flow-US$8.2M
Debt / Equity128%
Profitability & ownership
ROE-311.7%
ROA-96.1%
% insiders65.7%
% institutions5.8%
Last declaration on 6 August 2026
Declarations24 total
10,000 shares@ US$0.98160.043% mcap0.3% of flowCommon StockSEC:0001493152-26-036396:0
Canonical exit: 3 Nov 2026 (T+90)
75,000 shares@ US$0.94120.31% mcap2.5% of flowCommon StockSEC:0001493152-26-036169:0
Canonical exit: 1 Nov 2026 (T+90)
20,000 shares@ US$0.99760.7% of flowCommon StockSEC:0001493152-26-008039:0
Canonical exit: 25 May 2026 (T+90)
50,000 shares@ US$0.94561.6% of flowCommon StockSEC:0001493152-26-005773:0
Canonical exit: 7 May 2026 (T+90)
50,000 shares@ US$0.94551.6% of flowCommon StockSEC:0001493152-26-000114:0
Canonical exit: 31 Mar 2026 (T+90)
20,000 shares@ US$0.96550.7% of flowCommon StockSEC:0001493152-25-029796:0
Canonical exit: 30 Mar 2026 (T+90)
25,000 shares@ US$0.97030.8% of flowCommon StockSEC:0001493152-25-029257:0
Canonical exit: 24 Mar 2026 (T+90)
1,500 shares@ US$1.000.1% of flowCommon StockSEC:0001493152-25-025314:0
Canonical exit: 24 Feb 2026 (T+90)
20,000 shares@ US$0.94060.7% of flowCommon StockSEC:0001493152-25-025048:0
Canonical exit: 23 Feb 2026 (T+90)
359,713 shares@ US$1.3917.3% of flowCommon StockSEC:0001493152-25-020222:0
359,713 shares@ US$1.39100.0% of flowCommon StockSEC:0001493152-25-020221:0
3,598 shares@ US$1.39100.0% of flowCommon StockSEC:0001493152-25-020218:0
20,000 sharesCommon StockSEC:0001493152-25-020219:0
8,067 sharesCommon StockSEC:0001493152-24-040902:0
28,109 sharesCommon StockSEC:0001493152-24-040903:0
18,957 sharesCommon StockSEC:0001493152-24-040905:0
14,924 sharesCommon StockSEC:0001493152-24-040898:0
40,000 sharesCommon StockSEC:0001493152-24-040900:0
27,100 sharesCommon StockSEC:0001493152-24-040901:0
8,067 sharesCommon StockSEC:0001493152-24-040899:0
1,015,229 shares@ US$1.9773.7% of flowCommon StockSEC:0001493152-23-011239:0
Canonical exit: 3 Jul 2023 (T+90)
40,000 shares@ US$1.028100.0% of flowCommon StockSEC:0001493152-21-021048:0
Canonical exit: 18 Nov 2021 (T+90)
575,000 shares@ US$2.95100.0% of flowCommon StockSEC:0001493152-21-010669:0
24 of 24 declarations
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. (ticker: COCP) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. It is a clinical-stage biotech focused on discovering and developing broad-spectrum antiviral drug candidates designed to address important unmet medical needs. The company’s business model is centered on research and development, intellectual property creation, preclinical and clinical validation, and, ultimately, potential partnering, licensing, or commercialization of antiviral assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai))
The company was built around a technology-led antiviral strategy. According to recent SEC filings, Cocrystal is a Delaware corporation and its business address is in Bothell, Washington, placing it in one of the key life-science clusters of the Pacific Northwest. The latest available SEC materials describe Cocrystal as a clinical-stage biopharmaceutical company developing novel technologies and approaches intended to create first-in-class or best-in-class antiviral drug candidates. Since inception, its activities have mainly consisted of acquiring product and technology rights, raising capital, and performing research and development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai))
Read moreShow less
From a business-line perspective, Cocrystal is highly focused rather than diversified. Its core competency is viral replication inhibition, and its pipeline has been aimed at difficult-to-treat viral diseases. Public disclosures reference programs addressing influenza, viral gastroenteritis, COVID-19, and hepatitis. This narrow strategic focus can be attractive for investors looking for asymmetric upside from clinical progress, but it also means the equity case depends heavily on a limited number of assets and on the company’s ability to secure ongoing funding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1412486/000164117225027246/ex99-1.htm?utm_source=openai))
In competitive terms, Cocrystal operates in a crowded antiviral landscape that includes global pharmaceutical companies, specialized biotech developers, and alternative therapeutic approaches such as vaccines, antibodies, and symptom-management treatments. The company’s differentiation lies in its scientific approach to targeting viral replication mechanisms, with the goal of delivering broad-spectrum antiviral options. For investors, this translates into a classic small-cap biotech risk profile: meaningful scientific optionality, but also elevated execution risk, clinical uncertainty, and dilution risk if capital markets remain the main funding source. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001412486/000149315226023377/form10-q.htm?utm_source=openai))
Geographically, Cocrystal’s footprint is predominantly U.S.-centric, with operations and regulatory presence anchored in Bothell, Washington, and with equity market visibility through NASDAQ under the symbol COCP. Recent developments show that the company has continued to rely on capital markets to fund its programs, including a registered direct financing announced in September 2025, as well as subsequent operational updates and quarterly reporting in 2026. These disclosures reinforce that Cocrystal remains an investment-stage biotech, where cash runway, pipeline progress, and clinical milestones are the key drivers to watch. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-014819-index.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
